|
Middle East Fertility Society Journal
Middle East Fertility Society
ISSN: 1110-5690
Vol. 9, Num. 2, 2004, pp. 111-114
|
Untitled Document
Middle East Fertility Society Journal, Vol. 9, No. 2, 2004, pp. 111-114
DEBATE
Ovarian hyperstimulation syndrome: are preventive measures
effective?
Comment by: Karim H. Abd-El-Maeboud, M.D Cairo, Egypt
Code Number: mf04020
Treatment with exogenous gonadotrophic hormones has been used for more than
40 years. It has been more than two decades since they have been the "golden
standard" in assisted reproductive techniques. The key issue of using
gonadotropins was the improvement of pregnancy rates through retrieval of multiple
mature oocytes and increasing the number of replaced embryos (1). However,
one of the challenging complications is ovarian hyperstimulation syndrome (OHSS),
a dramatic and potentially life-threatening complication. Though the reported
incidence of the severe form of OHSS is small (0.5 to 5%), it is an iatrogenic
complication of a non-vital treatment (2). Despite a great deal of basic science
and clinical research, its pathophysiology is still poorly understood. Since
OHSS lacks a specific treatment, prevention has been in focus. Many risk factors
have been identified and various methods for preventing OHSS or diminishing
its severity have been suggested to avoid withholding hCG and cycle cancellation.
Though most of the investigators suggest the use of coasting to prevent OHSS,
well-designed studies to confirm its preference to other strategies and to
standardize application criteria are still lacking (3). Unfortunately, because
of inability to consistently identify patients at risk, there is no consensus
about its prevention strategies, mostly dealing rather late with the problem
when OHSS seems impending, and hence achieve only partial success.
Like many other diseases, OHSS is the result of what is inherited and what
is added. The role of the former may prevail completely (4) or partially (5).
The added factor, the stimulation protocol, should gain more attention. Ideally,
ovulation induction should stimulate the ovaries only to a desired level of
ovulation. No doubt the over-utilization of high-dose gonadotrophin protocols
by assisted reproductive units today carries some responsibility for the occurrence
of OHSS. In fact, refinements in drug regimens are needed not only to address
OHSS, but also other undesired consequences, such as multiple pregnancies and
increased costs. In this respect, there is need to reconsider the use of biochemical
markers to identify patients at risk before ovarian stimulation. Predicting
ovarian response to ovarian stimulation appears to have substantial benefit
in counseling and in tailoring each stimulation protocol according to the expected
ovarian response.
In recent years much new information related to regulation of human follicle
development has become available (6). Most of the studies concerning biochemical
markers of ovarian responsiveness (basal FSH, LH, E2, and inhibin-B) have been
directed towards identification of poor responders. In reproductive endocrinology,
the use of ratios of interacting markers (7, 8), rather than absolute values
(9), seems to be more informative. The basal FSH concentration is negatively
correlated with the ovarian stimulation response, reflecting the balance between
ovarian steroids and peptides and the hypothalamic-pituitary axis during follicular
recruitment but before selection of the dominant follicle. The less FSH stimulation
required to allow development of the follicular cohort, the better the quality
of the developing follicles, as gauged by response to gonadotropin stimulation
(10). It seems reasonable to assume that better quality is likely to be reflected
by increased E2 production with a subsequently higher basal E2 level. Hence,
the E2/FSH ratio would be more useful as a predictor of ovarian response in normally
ovulating women (8). It is already known that high basal E2 (above 290 pmol/L)
mostly reflects diminished ovarian reserve as a result of already advanced follicular
development with fewer follicles in the developing cohort that may still be rescued
with exogenous gonadotropin therapy (8, 11). Suppressed by way of a negative
feedback mechanism, cycle day 3 FSH levels appear to have diminished prognostic
accuracy in such a case, as the elevated basal E2 and low FSH values result in
a misleadingly high E2/FSH ratio. On the other hand, with lower basal E2 (at
or below 290 pmol/L), the F2/FSH ratio was found to be closely related to ovarian
reserve. The correlation of the E2/FSH ratio with parameters of ovarian response
to HMG stimulation was better, in terms of spectrum and precision, than either
basal F2 or FSH alone. In these cases, the basal E2 value reflects ovarian response
to the stimulating effect of basal FSH that is not yet suppressed by negative
feedback. Compared to others (12), E2/FSH ratio
represent an "endogenous dynamic" test for evaluation of ovarian reserve.
E2/FSH ratio of 35 or higher in these cases was found to be associated with a
relative risk of 12.7 for ovarian follicular overresponse (8), and hence seems
to be promising in predicting OHSS. Reviewing the data of Seifer et al. (13)
showed a better response to stimulation in association with high basal inhibin-B
and low basal FSH, inferring higher inhibin-B/FSH ratios. In fact, the combined
use of the gonadal steroid (E2) /FSH ratio and gonadal peptide (inhibin-B)/FSH
ratio is likely to reflect more closely the degree of readiness of the follicular
cohort and eventually enhance our present ability to predict outcome before starting
ovarian stimulation. The additional use of biophysical markers seems to be of
great value (14-16). These parameters are currently under investigation in a
larger patient sample to enhance prediction of ovarian responsiveness before
therapy begins.
The use of hMG in ART aims at multifollicular development and the step-down
hMG protocol seems rational as it mimics the physiological events during the
natural ovarian cycle (6). Earlier, the aim was to define general rules for
appropriate hMG dosage (17), though individualization, according to the characteristics
of the patient, should be also considered. The starting "recruiting" dose
is adjusted according to the predicted ovarian responsiveness, with stepping-down
to a "trophic" maintenance dose when ultrasonographic monitoring
(usually by stimulation day 7) reveals the advancement of a reasonable number
of antral follicles to 10-mm in diameter or more. However, many studies confirm
that the duration (related to the window concept) rather than the magnitude
(threshold concept) of FSH stimulation determines the number of developing
follicles (6). The impact of this concept, in management of patients with risk
factors, is that earlier close monitoring -serum E2 (18) and ultrasound (revealing
discrepancy in endometrial and follicular development)- could be of value in
disclosing early evolution of OHSS. This would allow earlier stepping-down
of hMG dose. The rescued follicles, with their enhanced sensitivity for FSH
as they mature, continue their development despite relatively low FSH concentrations,
incapable of stimulating growth of less mature follicles. Adopting this "early
step-down" approach might abolish OHSS through curtailing of the number
of functionally active small and medium-sized follicles, along with slowing
down of escalation in E2 level, both known as major risk factors (3). This
approach might be viewed as a further development of conventional (19) and
early (20) "coasting", yet avoiding the risk of abrupt E2 fall with
a reduction of the oocyte retrieval rate and embryo quality. In conclusion,
it seems that multiple strategies needs to be adopted to avoid OHSS, yet much
attention should be paid to those operating earlier during ART therapy.
REFERENCES
- Abd-el-Maeboud KH, Khalifa E-AM,
El-Hussein ES. An Increased Number of Replaced Embryos Counteracts the
Adverse Effect of Hydrosalpinges on IVF/ET Outcome. J Assist Reprod Genet
1998; 15(1):
22-26.
- Delvigne A, Rozenberg S. Epidemiology
and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum
Reprod Update 2002; 8(6):559-77.
- Aboulghar MA, Mansour RT. Ovarian
hyperstimulation syndrome: classifications and critical analysis of preventive
measures. Hum Reprod Update 2003; 9(3):275-89.4.
- Montanelli L, Delbaere A, Di Carlo C, Nappi C, Smits G, Vassart G, Costagliola
S. A mutation in the follicle-stimulating hormone receptor as a cause of
familial spontaneous ovarian hyperstimulation syndrome. J Clin Endocrinol
Metab 2004;
89(3):1255-8.
- McElhinney B, Ardill J, Caldwell
C, Lloyd F, McClure N. Ovarian hyperstimulation syndrome and assisted reproductive
technologies: why some and not others? Hum Reprod 2002; 17(6):1548-53.
- Fauser BCJM, Van Heusden AM.
Manipulation of Human Ovarian Function: Physiological Concepts and Clinical
Consequences. Endocrine Reviews 1997, 18(1):71-106.
- Abd-El-Maeboud KH, Eissa S, Kamel
AS. Altered endometrial progesterone/oestrogen receptor ratio in luteal
phase defect. Dis Markers 1997; 13:107-116.
- Abd-El-Maeboud, KH. Basal estradiol/follicle-stimulating
hormone ratio predicts ovarian response to gonadotropic stimulation in
patients with normal ovulation. Advances In Therapy 1999; 16(4):164-174.
- Kligman I, Rosenwaks Z. Differentiating
clinical profiles: predicting good responders, poor responders, and hyperresponders.
Fertil Steril 2001; 76(6):1185-90.
- Scott RT, Hofmann GE, Oehninger S, Muasher S.
Intercycle variability of day 3 follicle-stimulating hormone levels and
its effect on stimulation quality in in vitro fertilization. Fertil Steril
1990;
54(2):297-302.
- Smotrich DB, Widra FA, Gindoff PR, Levy MJ, Hall
JL, Stillman RJ. Prognostic value of day 3 estradiol on in vitro fertilization
outcome. Fertil Steril 1995; 64(6):1136-40.
- Fanchin R, de Ziegler D, Olivennes F, Taieb J,
Dzik A, Frydman R. Exogenous follicle stimulating hormone reserve test (EFFORT):
a simple and reliable screening test for detecting "poor responders" in
in-vitro fertilization. Hum Reprod 1994; 9(9):1607-11.
- Seifer DB, Lambert-Messerlian G, Hogan J, Gardiner
A, Blazar AS, Berk CA. Day 3 serum inhibinB is predictive of assisted reproductive
technologies outcome. Fertil Steril 1997; 67(1):110-4.
- 14. Frattarelli JL, Lauria-Costab DF, Miller BT,
Bergh PA, Scott RT. Basal antral follicle number and mean ovarian diameter
predict
cycle cancellation and ovarian responsiveness in assisted reproductive technology
cycles. Fertil Steril 2000; 74(3):512-7.
- Ng EHY, Tang OS, Ho PC. The significance of the
number of antral follicles prior to stimulation in predicting ovarian responses
in an IVF programme. Human Reprod 2000, 15(9):1937-42.
- Yong PYK, Baird DT, Thong KJ, McNeilly AS and
Anderson RA. Prospective analysis of the relationships between the ovarian
follicle cohort and basal FSH concentration, the inhibin response to exogenous
FSH and ovarian follicle number at different stages of the normal menstrual
cycle and after pituitary down-regulation. Human Reproduction 2003, 18(1):35-44.
- van Hooff MHA. The human menopausal gonadotropin
(HMG) dose in in vitro fertilization (IVF): what is the optimal dose? J
Assist Reprod Genet 1995; 12(4):233-5.
- Schoot DC, Hop WC, de Jong FH, van Dessel TJ,
Fauser BC. Initial estradiol response predicts outcome of exogenous gonadotropins
using a step-down dose regimen for induction of ovulation in polycystic
ovary syndrome. Fertil Steril 1995; 64(6):1081-7.
- Levinsohn-Tavor O, Friedler S, Schachter M, Raziel
A, Strassburger D, Ron-El R. Coasting-what is the best formula? Hum Reprod
2003; 18(5):937-40.
- Egbase PE, Al-Sharhan M, Grudzinskas JG. 'Early
coasting' in patients with polycystic ovarian syndrome is consistent with
good clinical outcome. Hum Reprod 2002; 17(5):1212-6.
Karim H.I. Abd-El-Maeboud, M.D.
Professor of OB/GYN
Ain Shams University
Cairo, Egypt
© Copyright 2004 - Middle East Fertility Society
|